EP-80317

1 study on EP-80317 curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.

Bottom line: TitrateLab currently curates 1 dated study on EP-80317. The source summaries below describe published research; they do not establish product quality, safety, or clinical suitability.

EP-80317 studies and clinical research

2026-04-03 PubMed · in vitro · n preclinical

Hexarelin and EP-80317 suppress CALU-1 lung carcinoma cell growth via non-GHS-R1a receptor

**Peptidyl GHS compounds like hexarelin may carry direct anticancer activity in lung carcinoma independent of their GH-releasing function**, a mechanistic split with major implications for therapeutic development and …

Research tools

Free, no account — handy when you're working with EP-80317.

Reconstitution calculator Bac water, concentration & insulin-unit math Verify a COA Look up a report number against our corpus

TitrateLab PRO

Unlock the complete evidence trail

Pro members save studies and unlock the full evidence breakdown and vendor lab data.

Complete vendor lab histories
Every linked certificate on file
Batch-level purity and quantity detail
Thousands of community reviews

Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.

$14 monthly or $88/year

Create an account

TitrateLab

You must be 21 or older to enter.

TitrateLab provides research-use information on peptides for adults. Confirm your age to continue.

For research purposes only. Not for human consumption. By entering you agree to our Terms & Privacy.

EP-80317 studies and clinical research

Hexarelin and EP-80317 suppress CALU-1 lung carcinoma cell growth via non-GHS-R1a receptor

Research tools